PharmaNutra stock
Price history
+71.60% over the period1 year: from €50.00 (November 20, 2025) to €85.80 (November 20, 2026), +71.60%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €85.80 |
| October 30, 2026 | €71.00 |
| September 30, 2026 | €73.10 |
| August 31, 2026 | €82.00 |
| July 31, 2026 | €83.20 |
| June 30, 2026 | €87.70 |
| May 29, 2026 | €90.60 |
| April 30, 2026 | €78.80 |
| March 31, 2026 | €78.70 |
| February 27, 2026 | €67.00 |
| January 30, 2026 | €63.10 |
| December 30, 2025 | €54.30 |
| November 28, 2025 | €58.00 |
| November 20, 2025 | €50.00 |
At a glance
The company
Research, develop and market food supplements, medical devices and raw materials for nutraceutical and pharmaceutical industries
Latest results
Quarter to September 30, 2026 · EPS €0.74 (estimate €0.83)
TickerLandia's take on PharmaNutra
- Pricier than usual relative to earnings: P/E on the latest fiscal year 41 vs a median of 27 over its last 9 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 37 vs 20 (+88%) in a group of 9.
- Strong point: Market momentum (77/100 in its group). Weak point: Dividend (50/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.53% from the 52-week high
Analysts · 3 analysts
Average target€96.00+11.89% vs. price
Buy 3 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: PharmaNutra
Compared with similar companies: strong momentum, high growth, and high price.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh75
How much it costs relative to what it produces.
Metric Value Position in group Price/book 10.9 91 Price/sales 5.60 75 EV/EBITDA 23.0 71 Forward P/E 26.4 68 P/E (trailing 12 months) 36.7 70 Profitabilityhigh66
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 22.0% 55 ROE 32.4% 96 ROA 16.4% 99 Gross margin 50.9% 22 Net margin 15.4% 58 Earnings stabilityhigh66
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.5% 70 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh76
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +16.74% 86 Revenue growth (year over year) +16.90% 61 Earnings growth (year over year) +48.40% 81 Financial strengthhigh63
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.04 64 Interest coverage 43.9 71 Current ratio 2.11 53 Debt/equitycounts in reverse: lower means more financial strength 0.26 64 Dividendaverage50
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 9 years 33 Dividend yield 1.4% 40 Payout ratio 50.4% 76 Market momentumstrong77
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +14.12% 85 1-year return +71.60% 96 Relative strength (6 months) −1.54% 52 Distance from 200-day average +8.34% 77 Riskaverage44
How much the price swings.
Metric Value Position in group Volatility (60 days) 38.2% 79 Maximum drawdown (12 months) 24.4% 50 Beta (1 year) 0.11 4
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
PharmaNutra is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), PharmaNutra's P/E today is 41.1, above the median of its last 9 fiscal years (26.8; between 17.1 and 53.0 from 2017 to 2025). PharmaNutra's P/E (trailing 12 months): 36.7, +88% against the median of a group of 9 similar companies (19.5).
Compared with 9 similar companies
| Metric | PharmaNutra | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 36.7 | High | |
| Forward P/E | 26.4 | High | |
| Operating margin | 22.0% | Middle | |
| ROE | 32.4% | High | |
| Debt/equity | 0.26 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: PharmaNutra. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€40.5M
Latest quarter · Q2 2026
Net income
€6.47M
Latest quarter · Q2 2026
Quarterly net margin
16.0%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €834.95M
- P/E
- 36.7
- EPS
- €2.38
- Volume
- 9.76K
- Daily trading
- €1.22M
- Dividend yield
- 1.40%
- Last ex-dividend on May 4, 2026
How PharmaNutra is changing
All resultsRevenue grew 18.4% a year on average over the last 5 years
Operating margin fell from 27.8% to 22.0%
Free cash flow equal to 64% of net income
Returns
PharmaNutra returns with dividends
€1,000 invested in PharmaNutra 5 years ago, on November 22, 2021, would be worth €1,265 today with dividends reinvested: +26.48% in total, +4.82% per year. On price alone it would be €1,172 (+17.21%).
| Period | PharmaNutra | FTSE MIB | €1,000 becomes |
|---|---|---|---|
| 1 month | +21.02% | −0.75% | €1,210 |
| 6 months | −2.50% | −0.97% | €975 |
| Year to date | +58.01% | +8.36% | €1,580 |
| 1 year | +74.18% | +13.48% | €1,742 |
| 3 years | +71.10% | +64.86% | €1,711 |
| 5 years | +26.48% | +77.86% | €1,265 |
Over the last 6 months it has done better than 20% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE MIB: price only. Calculate your investment
The chart in detail
PharmaNutra: technical analysis
PharmaNutra shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 7.6% below its all-time closing high (€92.90, June 8, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 72
- Above 70: a strong rise in a short time
- vs 200-session average
- +8.34%
Active signals
RSI above 70: the stock has risen a lot in a short time.
since November 10, 2026
Support and resistance
Price areas where PharmaNutra has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€91.10+6.18%2 touches, last on July 8, 2026
- Last price€85.80
- Support€85.60−0.23%3 touches, last on August 11, 2026
- Support€83.47−2.72%3 touches, last on September 8, 2026
- Support€81.00−5.59%2 touches, last on July 30, 2026
Volatility and risk
Over the last year it has moved little with the FTSE MIB.
- Beta (1 year) vs FTSE MIB
- 0.11
- Volatility (60 sessions, annualised)
- 38.2%
- Largest fall in the last year
- −24.43%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
PharmaNutra: seasonality
Average monthly price change over 10 years
Over the last 10 years, the strongest month for PharmaNutra has been November: +5.23% on average, positive in 7 years out of 9. The weakest has been September: −2.10% on average, positive in 4 years out of 10.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.13% | −0.43% | 4 of 9 |
| February | +0.30% | +0.30% | 5 of 9 |
| March | +0.33% | +0.29% | 5 of 9 |
| April | +0.89% | +1.76% | 6 of 9 |
| May | +3.05% | +1.24% | 5 of 9 |
| June | +3.36% | −3.20% | 4 of 9 |
| July | +0.71% | −0.43% | 3 of 9 |
| August | +3.64% | +0.61% | 6 of 10 |
| September | −2.10% | −2.14% | 4 of 10 |
| October | +1.79% | +0.70% | 6 of 10 |
| November | +5.23% | +4.41% | 7 of 9 |
| December | +4.39% | +1.20% | 5 of 9 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
PharmaNutra and its competitors
Customers in Europe, the Middle East, the Far East, North America, South America and other regions buy the food supplements and medical devices that Pharmanutra develops, makes and markets. Its nutraceutical operations also supply raw materials and active ingredients to food, pharmaceutical and dietary supplement manufacturers. Among its branded products, Sucrosomial is a delivery system designed to improve nutrient absorption while limiting gastrointestinal side effects, and Cetylated Fatty Acids supports muscles and joints after physical therapy and training.
- Headquarters
- Pisa, Italy
- Employees
- 146
- Founded
- 2000
- Chief executive
- Roberto Lacorte
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| PharmaNutraPHN | $917.61M | 22.0% | 36.7 | −2.50% |
| EvotecEVT | $489.39M | -18.0% | — | −48.86% |
| Faes FarmaFAE | $1.65B | 13.0% | 17.9 | +4.66% |
| FagronFAGR | $1.97B | 14.3% | 19.5 | −0.20% |
| AlmirallALM | $2.45B | 9.6% | 30.2 | −9.84% |
| Siegfried HoldingSFZN | $3.4B | 16.7% | 16.7 | −19.46% |
Same industry or related industries, similar size. Compare PharmaNutra with its competitors · Full profile
